Ribociclib: all 118 studies that test it

Page 1 of 2. Open to participants first (20), then studies with results posted, then the rest; newest registration first within each.

• A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruitingNCT07647328Phase 3
• A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingNCT07618390Phase 2
• Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant ChemotherapyRecruitingNCT07400523Phase 3
• Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerRecruitingNCT07195227Phase 2
• Ribociclib for HR-positive HER2-negative Metastatic Breast CancerRecruitingNCT07164976Phase 1/2
• Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast CancerNot yet recruitingNCT06849947Phase 2
• The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant TreatmentNot yet recruitingNCT06810492Not applicable
• Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsRecruitingNCT06726148Phase 1/2
• T-DM1 Combined With CDK4/6 Inhibitor RibociclibEnrolling by invitationNCT06481956Phase 2
• Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingNCT06409390Phase 2
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3
• The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyRecruitingNCT06377852Phase 3
• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingNCT06062498Phase 2
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerRecruitingNCT05467891Phase 2
• Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer PatientsRecruitingNCT05452213Phase 4
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingNCT04802759Phase 1/2
• A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingNCT04116541Phase 2
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
• Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast CancerTerminatedNCT05384119Phase 1Results posted
• Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based CohortsTerminatedNCT04657679Phase 4Results posted
• Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By GenomicsTerminatedNCT04315233Phase 1Results posted
• Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast CancerCompletedNCT03839823Phase 2Results posted
• A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for ResectionCompletedNCT03834740Early Phase 1Results posted
• Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast CancerCompletedNCT03822468Phase 2Results posted
• Ribociclib and Letrozole Treatment in Ovarian CancerActive, not recruitingNCT03673124Phase 2Results posted
• Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.CompletedNCT03671330Phase 2Results posted
• Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast CancerCompletedNCT03477396Phase 2Results posted
• Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantTerminatedNCT03439046Phase 3Results posted
• Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain TumorsCompletedNCT03387020Phase 1Results posted
• Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast CancerCompletedNCT03096847Phase 3Results posted
• Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast CancerCompletedNCT03078751Phase 2Results posted
• A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine TumorsCompletedNCT03070301Phase 2Results posted
• A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/RibociclibTerminatedNCT03050398Phase 3Results posted
• LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to ChemotherapyCompletedNCT02985125Phase 1/2Results posted
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCCompletedNCT02941926Phase 3Results posted
• Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.CompletedNCT02732119Phase 1/2Results posted
• Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast CancerActive, not recruitingNCT02712723Phase 2Results posted
• Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial CancerCompletedNCT02657928Phase 2Results posted
• Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast CancerCompletedNCT02632045Phase 2Results posted
• A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation TherapyTerminatedNCT02607124Phase 1/2Results posted
• TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast CancerCompletedNCT02586675Phase 1Results posted
• Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma ExpressionTerminatedNCT02555189Phase 1/2Results posted
• LEE001 and Chemoembolization In Patients With Advanced Hepatocellular CarcinomaTerminatedNCT02524119Phase 2Results posted
• LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPCCompletedNCT02494921Phase 1/2Results posted
• Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.CompletedNCT02422615Phase 3Results posted
• Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut OriginCompletedNCT02420691Phase 2Results posted
• A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent ProgressionCompletedNCT02300987Phase 2Results posted
• Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerCompletedNCT02278120Phase 3Results posted
• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)CompletedNCT02187783Phase 2Results posted
• LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF MelanomaCompletedNCT02159066Phase 2Results posted
• Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast CancerCompletedNCT01958021Phase 3Results posted
• A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)TerminatedNCT01919229Phase 2Results posted
• A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant MelanomaCompletedNCT01781572Phase 1/2Results posted
• Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.TerminatedNCT01777776Phase 1/2Results posted
• Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and NeuroblastomaTerminatedNCT01747876Phase 1Results posted
• Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in EgyptCompletedNCT07487129Phase 4
• First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast CancerCompletedNCT06375707Phase 2
• Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast CancerActive, not recruitingNCT05996107Phase 1
• [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerActive, not recruitingNCT05870579Phase 1
• Phase IIIb Study of Ribociclib + ET in Early Breast CancerActive, not recruitingNCT05827081Phase 3
• Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 GenotypeWithdrawnNCT05691400Phase 4
• Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)WithdrawnNCT05664893Phase 1/2
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)Active, not recruitingNCT05573555Phase 1/2
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruitingNCT05508906Phase 1
• Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid TumorsTerminatedNCT05429502Phase 1
• Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerActive, not recruitingNCT05319873Phase 1/2
• Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruitingNCT05238922Phase 1
• Roll-over Study to Allow Continued Access to RibociclibActive, not recruitingNCT05161195Phase 4
• Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active, not recruitingNCT04862663Phase 3
• Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
• Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain MetastasesWithdrawnNCT04585724Phase 1
• Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaActive, not recruitingNCT04417621Phase 2
• Ribociclib and Spartalizumab in R/M HNSCCStatus unknownNCT04213404Phase 1
• Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBCActive, not recruitingNCT04055493Phase 3
• Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected MalignanciesTerminatedNCT04000529Phase 1
• FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast CancerActive, not recruitingNCT03944434Phase 2
• Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer PatientsStatus unknownNCT03913234Phase 1/2
• Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBCTerminatedNCT03905343Phase 3
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerActive, not recruitingNCT03701334Phase 3
• Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingNCT03616587Phase 1
• Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast CancerCompletedNCT03555877Phase 2
• A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)CompletedNCT03355794Phase 1
• CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast CancerActive, not recruitingNCT03285412Phase 2
• Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.CompletedNCT03248427Phase 2
• Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid TumorsCompletedNCT03237390Phase 1
• Impact of Ribociclib on Head and Neck Squamous Cell CancerTerminatedNCT03179956Early Phase 1
• Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)Active, not recruitingNCT03114527Phase 2
• A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated LiposarcomaStatus unknownNCT03096912Phase 2
• Ribociclib and Bicalutamide in AR+ TNBCActive, not recruitingNCT03090165Phase 1/2
• Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast CancerWithdrawnNCT03081234Phase 3
• Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian CancerCompletedNCT03056833Phase 1
• Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by SurgeryCompletedNCT03009201Phase 1
• A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial CarcinomaActive, not recruitingNCT03008408Phase 2
• Ribociclib (LEE011) Rollover Study for Continued AccessActive, not recruitingNCT02934568Phase 2
• Ribociclib (LEE011) in Preoperative Glioma and Meningioma PatientsActive, not recruitingNCT02933736Early Phase 1
• Next Generation Personalized Neuroblastoma TherapyTerminatedNCT02780128Phase 1
• Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast CancersTerminatedNCT02734615Phase 1
• Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid TumorsTerminatedNCT02703571Phase 1

← Ribociclib overview